SYK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stryker Corp (SYK) is not a strong buy at this moment for a beginner investor with a long-term focus. While the stock has shown some positive momentum in the short term, the lack of significant positive catalysts, mixed analyst ratings, and recent hedge fund selling suggest a cautious approach. Given the investor's preference for long-term stability, it may be better to wait for clearer signs of growth or improved sentiment before investing.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 51.945, and moving averages are converging, suggesting no strong trend. The stock is trading near its pivot point (307.398) with resistance at 313.617 and support at 301.179.
The company has indicated a recovery from Q1 disruptions, with management providing visibility into recovering lost revenue by year-end. Analysts see potential in healthy procedure growth, robust hospital capital spending, and new product launches.
Hedge funds are selling, with a 119.77% increase in selling activity over the last quarter. Analysts have lowered price targets due to concerns about utilization risks, inflation headwinds, and mixed Q1 results impacted by a cyber-attack. Additionally, there is disillusionment regarding industry consolidation trends.
No financial data available for the latest quarter. However, analysts have noted that Q1 organic growth slowed significantly to 2.4% due to a cyber incident, and the company is relying on backlogs and revenue-recognition tailwinds to meet FY26 guidance.
Analyst ratings are mixed. Several firms lowered their price targets, citing risks like inflation, utilization, and Q1 disruptions. However, some analysts maintain Buy or Outperform ratings, highlighting the company's recovery potential and strong fundamentals in the MedTech sector.
